News
Abu Dhabi Scientists Create Electronic Appetite Regulation Pill
The tiny device utilizes electrodes to stabilize and regulate the gut-brain axis, which can help control appetite and treat several diseases.
A research team from NYU Abu Dhabi (NYUAD), overseen by Professor Khalil Ramadi, has created a groundbreaking “ingestible electroceutical device” known as the FLASH system. The pill-shaped device modulates the signaling pathway between the digestive tract and the central nervous system and is administered like a regular ingestible capsule tablet.
Featuring surface electrodes that deliver stimulation to the stomach’s mucosal tissues, the non-invasive device bypasses gastric acids to achieve direct electrode-to-tissue contact. The ingestible pill is powered by tiny batteries, delivering stimulation for around 20 minutes before being excreted by the body — a process that can take up to two weeks, depending on the size of the human or animal test subject.
“FLASH is one of the first ingestible electroceuticals that can regulate precise neurohormonal circuits while avoiding the discomfort patients can experience with invasive treatments,” says Professor Khalil Ramadi, NYU Abu Dhabi.
Researchers on the FLASH project were inspired by the unique skin surface properties of the Australian Thorny Devil Lizard, whose skin can efficiently wick away surface moisture. The pill replicates this process by using grooved surface patterns and hydrophilic properties that enable it to be ingested and excreted without side effects.
Also Read: Sultan Al Neyadi Becomes The First Ever Arab To Spacewalk
During testing, scientists noted that the capsule modulated the release of the hormone ghrelin, which the body uses to stimulate hunger. Regular hormone medications have poor bioavailability in oral form, requiring an injection to administer. The FLASH system, on the other hand, can target very specific gastric-hormonal pathways through simple oral administration.
The FLASH pill shows promise against a wide range of diseases, including metabolic, gastrointestinal, and neuropsychiatric disorders. Unfortunately, the device requires further preclinical testing before being ready for the public market. However, the development team has set a goal of creating an advanced prototype for human trials within five years.